For U.S. Residents Only
+|Aa|-

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.

Click here for additional Important Safety Information.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Renassist

Having trouble with Renvela prescription coverage? Renassist® may be able to help. Learn more

Renvela® powder preparation video

Learn to prepare Renvela powder—the only phosphate binder available in both tablet and powder form. View now

About Renvela® (sevelamer carbonate): available in tablet or powder form

Indication

Renvela® (sevelamer carbonate) is used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Why Renvela?

In addition to dialysis, your doctor may prescribe Renvela as an important part of your treatment plan. Renvela can help control phosphorus in your blood.

Renvela: here for you

  • Renvela is the only phosphate binder available in both tablet and powder form.
  • Renvela is not absorbed, so it does not build up in your body.
  • Are you having trouble with Renvela prescription coverage? A Renassist® case manager may be able to help. Learn more at Renassist.com.

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

The health information contained herein is provided for general education purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.